Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ARIAD Pharmaceuticals Inc (NASDAQ:ARIA)

13.71
Delayed Data
As of Sep 29
 -0.43 / -3.04%
Today’s Change
4.37
Today|||52-Week Range
14.26
+119.36%
Year-to-Date
Biotech Stock Mailbag: Dynavax, Puma, Ariad
7:06am / TheStreet.com - Paid Partner Content
Dipexium Pharmaceuticals (DPRX) Worth a Look: Stock Up 8.8%
Sep 28 / Zacks.com - Paid Partner Content
AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso
Sep 28 / Zacks.com - Paid Partner Content
Ariad Pharmaceuticals (ARIA) Stock Climbs, Coverage Initiated at Leerink
Sep 26 / TheStreet.com - Paid Partner Content
Ardelyx (ARDX) Worth Watching: Stock Rises 6.1% in Session
Sep 28 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close14.14
Today’s open14.03
Day’s range13.57 - 14.15
Volume5,323,596
Average volume (3 months)5,329,311
Market cap$2.7B
Dividend yield--
Data as of 09/29/2016

Growth & Valuation

Earnings growth (last year)-41.38%
Earnings growth (this year)+92.50%
Earnings growth (next 5 years)+41.39%
Revenue growth (last year)+12.70%
P/E ratioNM
Price/Sales9.93
Price/Book--

Competitors

 Today’s
change
Today’s
% change
KITEKite Pharma Inc-0.48-0.85%
BLUEbluebird bio Inc-2.70-3.91%
RDUSRadius Health Inc-2.93-5.04%
NKTRNektar Therapeutics-0.72-4.07%
Data as of 09/29/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)-$0.20
Annual revenue (last year)$118.8M
Annual profit (last year)-$231.2M
Net profit margin-194.57%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Paris Panayiotopoulos
Chief Financial Officer, Treasurer &
Executive VP
Manmeet Singh Soni
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Search for Jobs